
Claims

1. Use of compound A in the manufacture of a solid preparation for the treatment and/or prevention of a blood coagulation-related disease, wherein the solid preparation comprises a therapeutically effective amount of compound A with a particle size D90 of 3 μm to 8 μm, a single daily dose of the solid preparation provides a mean C_{max} of 0.8 ng/ml to 1.2 ng/ml of compound A, and compound A is (7aS, 2'S)-2-oxo-clopidogrel represented by:



.

2. The use according to claim 1, wherein the therapeutically effective amount is 4 mg to 5.5 mg in a single daily dose, and preferably, the therapeutically effective amount is 4 mg to 5 mg in a single daily dose.

3. The use according to any one of claims 1 to 2, wherein the single daily dose provides a mean C_{max}/C_{12h} of 8 to 12 of compound A.


4. The use according to any one of claims 1 to 2, wherein the solid formulation comprises a binder.

5. The use according to any one of claims 1 to 2, wherein the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean C_{max} of compound A ranging from 80% to 125% of 0.8 ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean C_{max} of compound A ranging from 80% to 125% of 0.9 ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean C_{max} of compound A ranging from 80% to 125% of 1.2 ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-48h)}$ of compound A ranging from 80% to 125% of 2.3h*ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-48h)}$ of compound A ranging from 80% to 125% of 3.0h*ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-48h)}$ of compound A ranging from 80% to 125% of 3.5h*ng/ml; or the therapeutically effective

amount is 4 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-t)}$ of compound A ranging from 80% to 125% of 2.3h*ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-t)}$ of compound A ranging from 80% to 125% of 3.0h*ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-t)}$ of compound A ranging from 80% to 125% of 3.5h*ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-\infty)}$ of compound A ranging from 80% to 125% of 2.7h*ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-\infty)}$ of compound A ranging from 80% to 125% of 3.5h*ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-\infty)}$ of compound A ranging from 80% to 125% of 4.2h*ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-12h)}$ of an active metabolite H4 ranging from 80% to 125% of 13h*ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-12h)}$ of an active metabolite H4 ranging from 80% to 125% of 14h*ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-12h)}$ of an active metabolite H4 ranging from 80% to 125% of 18.5h*ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-t)}$ of an active metabolite H4 ranging from 80% to 125% of 13h*ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-t)}$ of an active metabolite H4 ranging from 80% to 125% of 14h*ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-t)}$ of an active metabolite H4 ranging from 80% to 125% of 18.5h*ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-\infty)}$ of an active metabolite H4 ranging from 80% to 125% of 13.5h*ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-\infty)}$ of an active metabolite H4 ranging from 80% to 125% of 15h*ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-\infty)}$ of an active metabolite H4 ranging from 80% to 125% of 19h*ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean C_{max} of an active metabolite H4 ranging from 80% to 125% of 12.5ng/ml; or the

therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean C_{max} of an active metabolite H4 ranging from 80% to 125% of 14ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean C_{max} of an active metabolite H4 ranging from 80% to 125% of 17ng/ml.

6. A pharmaceutical composition for use in the treatment and/or prevention of a blood coagulation-related disease, comprising a therapeutically effective amount of compound A and at least one pharmaceutically acceptable excipient, wherein compound A has a particle size D90 of 3μm to 8μm, the excipient comprises a binder, and compound A is (7aS, 2'S)- 2-oxo-clopidogrel represented by:



.

7. The pharmaceutical composition according to claim 6, wherein the therapeutically effective amount is 4 mg to 5.5 mg in a single daily dose, and preferably, the therapeutically effective amount is 4 mg to 5 mg in a single daily dose; or a single daily dose provides a mean C_{max} of compound A of 0.8ng/ml to 1.2ng/ml following administration of a therapeutically effective amount of the pharmaceutical composition to a human subject.

8. The pharmaceutical composition according to claim 6, wherein the binder is selected from the group consisting of gum arabic, gelatin, sodium carboxymethylcellulose, methylcellulose, copovidone, polyvidone, hypromellose, and a combination thereof.

9. The pharmaceutical composition according to any one of claims 6 to 7, wherein the pharmaceutical composition further comprises a filler, a disintegrant and a lubricant as a pharmaceutically acceptable excipient; preferably, the filler is selected from the group consisting of mannitol, sorbitol, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, calcium sulfate dihydrate, sucrose, dextrin, microcrystalline cellulose, lactose, starch, pregelatinized starch, powdered sugar, dextrin, and a combination thereof;

the disintegrant is selected from the group consisting of low-substituted hydroxypropyl cellulose, polacrilin potassium, crospovidone, cross-linked sodium carboxymethyl cellulose,

sodium carboxymethyl starch, dry starch, and a combination thereof; and

the lubricant is selected from the group consisting of magnesium stearate, sodium stearic fumarate, silicon dioxide, talc, polyethylene glycol-like substances, hydrogenated vegetable oils, sodium dodecyl sulfate, and a combination thereof.

10. The pharmaceutical composition according to any one of claims 6 to 9, wherein the pharmaceutical composition has a dissolution amount of greater than or equal to 70% within 30 minutes in an acetate buffer solution with a pH of 4.5, as determined according to Method 2 of China Pharmacopoeia 2020 edition General Principles 0931; or the pharmaceutical composition has a dissolution percentage of greater than or equal to 85% within 60 minutes in an acetate buffer solution with a pH of 4.5, as determined according to Method 2 of China Pharmacopoeia 2020 edition General Principles 0931; or the single daily dose provides a mean C_{max}/C_{12h} of compound A of 8 to 12; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean C_{max} of compound A ranging from 80% to 125% of 0.8 ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean C_{max} of compound A ranging from 80% to 125% of 0.9 ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean C_{max} of compound A ranging from 80% to 125% of 1.2 ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-48h)}$ of compound A ranging from 80% to 125% of 2.3h*ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-48h)}$ of compound A ranging from 80% to 125% of 3.0h*ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-48h)}$ of compound A ranging from 80% to 125% of 3.5h*ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-t)}$ of compound A ranging from 80% to 125% of 2.3h*ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-t)}$ of compound A ranging from 80% to 125% of 3.0h*ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-t)}$ of compound A ranging from 80% to 125% of 3.5h*ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-\infty)}$ of compound A ranging from 80% to 125% of 2.7h*ng/ml; or the therapeutically

effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-\infty)}$ of compound A ranging from 80% to 125% of 3.5h*ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-\infty)}$ of compound A ranging from 80% to 125% of 4.2h*ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-12h)}$ of an active metabolite H4 ranging from 80% to 125% of 13h*ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-12h)}$ of an active metabolite H4 ranging from 80% to 125% of 14h*ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-12h)}$ of an active metabolite H4 ranging from 80% to 125% of 18.5h*ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-t)}$ of an active metabolite H4 ranging from 80% to 125% of 13h*ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-t)}$ of an active metabolite H4 ranging from 80% to 125% of 14h*ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-t)}$ of an active metabolite H4 ranging from 80% to 125% of 18.5h*ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-\infty)}$ of an active metabolite H4 ranging from 80% to 125% of 13.5h*ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-\infty)}$ of an active metabolite H4 ranging from 80% to 125% of 15h*ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean $AUC_{(0-\infty)}$ of an active metabolite H4 ranging from 80% to 125% of 19h*ng/ml; or the therapeutically effective amount is 4 mg in a single daily dose, and the single daily dose provides a mean C_{max} of an active metabolite H4 ranging from 80% to 125% of 12.5ng/ml; or the therapeutically effective amount is 4.5 mg in a single daily dose, and the single daily dose provides a mean C_{max} of an active metabolite H4 ranging from 80% to 125% of 14ng/ml; or the therapeutically effective amount is 5.5 mg in a single daily dose, and the single daily dose provides a mean C_{max} of an active metabolite H4 ranging from 80% to 125% of 17ng/ml.